BROOKS LABORATORIES LTD.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹107.73
- Today's High:
- ₹109
- Open Price:
- ₹107.73
- 52W Low:
- ₹57.05
- 52W High:
- ₹141.8
- Prev. Close:
- ₹109.92
- Volume:
- 9481
Company Statistics
- Market Cap.:
- ₹2.56 billion
- Book Value:
- 34.925
- Revenue TTM:
- ₹617.84 million
- Operating Margin TTM:
- -37.68%
- Gross Profit TTM:
- ₹128.06 million
- Profit Margin:
- -29.89%
- Return on Assets TTM:
- -13.68%
- Return on Equity TTM:
- -29.82%
Company Profile
BROOKS LABORATORIES LTD. had its IPO on under the ticker symbol BROOKS.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. BROOKS LABORATORIES LTD. has a staff strength of 0 employees.
Stock update
Shares of BROOKS LABORATORIES LTD. opened at ₹107.73 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹107.73 - ₹109, and closed at ₹108.85.
This is a -0.97% slip from the previous day's closing price.
A total volume of 9,481 shares were traded at the close of the day’s session.
In the last one week, shares of BROOKS LABORATORIES LTD. have increased by +9.32%.
BROOKS LABORATORIES LTD.'s Key Ratios
BROOKS LABORATORIES LTD. has a market cap of ₹2.56 billion, indicating a price to book ratio of 4.6094 and a price to sales ratio of 3.3983.
In the last 12-months BROOKS LABORATORIES LTD.’s revenue was ₹617.84 million with a gross profit of ₹128.06 million and an EBITDA of ₹-162629504. The EBITDA ratio measures BROOKS LABORATORIES LTD.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BROOKS LABORATORIES LTD.’s operating margin was -37.68% while its return on assets stood at -13.68% with a return of equity of -29.82%.
In Q2, BROOKS LABORATORIES LTD.’s quarterly earnings growth was a positive 0% while revenue growth was a negative 8.3%.
BROOKS LABORATORIES LTD.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-12.87 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BROOKS LABORATORIES LTD.’s profitability.
BROOKS LABORATORIES LTD. stock is trading at a EV to sales ratio of 3.8377 and a EV to EBITDA ratio of -11.4443. Its price to sales ratio in the trailing 12-months stood at 3.3983.
BROOKS LABORATORIES LTD. stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹1.10 billion
- Total Liabilities
- ₹330.21 million
- Operating Cash Flow
- ₹4.95 million
- Capital Expenditure
- ₹4.68 million
- Dividend Payout Ratio
- 0%
BROOKS LABORATORIES LTD. ended 2025 with ₹1.10 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.10 billion while shareholder equity stood at ₹739.53 million.
BROOKS LABORATORIES LTD. ended 2025 with ₹0 in deferred long-term liabilities, ₹330.21 million in other current liabilities, 247028000.00 in common stock, ₹492.50 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹10.52 million and cash and short-term investments were ₹13.78 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.00.
BROOKS LABORATORIES LTD.’s total current assets stands at ₹276.06 million while long-term investments were ₹0 and short-term investments were ₹3.03 million. Its net receivables were ₹127.54 million compared to accounts payable of ₹233.70 million and inventory worth ₹113.03 million.
In 2025, BROOKS LABORATORIES LTD.'s operating cash flow was ₹4.95 million while its capital expenditure stood at ₹4.68 million.
Comparatively, BROOKS LABORATORIES LTD. paid ₹0 in dividends in 2025.
Other key metrics
- Current Trading Price
- ₹108.85
- 52-Week High
- ₹141.8
- 52-Week Low
- ₹57.05
- Analyst Target Price
- ₹
BROOKS LABORATORIES LTD. stock is currently trading at ₹108.85 per share. It touched a 52-week high of ₹141.8 and a 52-week low of ₹141.8. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹92.32 and 200-day moving average was ₹87.25 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6751.2% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About BROOKS LABORATORIES LTD.
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Brooks Laboratories Limited manufactures and sells pharmaceuticals in India and internationally. It offers carbapenem drugs; tablets; dry syrup; liquid and dry power injections; and eye/ear drops. The company was incorporated in 2002 and is based in Mumbai, India.